SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as shareholders voice intense dissatisfaction with the company's $18-per-share sale to Garda Therapeutics, arguing the price significantly undervalues their core growth assets. Investors are actively debating the lack of transparency in the strategic review process, the removal of potential long-term upside in Rolvedon and Sympazan, and the perceived conflict of interest regarding executive compensation.

Global X Funds - Global X Defense Tech ETF

Global X Defense Tech ETF

The Global X Defense Tech ETF is trending as investors capitalize on surging worldwide military spending and a shift toward tech-driven, autonomous warfare. The community is actively discussing its potential for long-term growth driven by geopolitical tensions, with many highlighting its strategic exposure to both domestic defense contractors and international aerospace leaders.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending due to the launch of its ONBERG joint venture in Germany, which focuses on autonomous drone defense systems and has already secured live demonstrations. While the company is expanding its operational footprint across Europe, the stock continues to be a battleground between investors bullish on its defense technology integration and skeptics focused on dilution and ongoing legal challenges.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is surging as the stock breaks toward all-time highs, fueled by an $11.6 billion acquisition of satellite operator Globalstar that investors view as a strategic push to bolster its Project Kuiper network against competition. The community is actively debating whether this move signals a broader transition into a long-term 'harvesting' phase for the company, while many are focused on the stock's impressive momentum and its role as a core infrastructure play in the AI and satellite-connectivity race.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is attracting significant attention as investors anticipate upcoming data readouts and regulatory catalysts, with the community actively debating the potential for a short squeeze given high short interest and a limited effective float. Supporters are highlighting the company's clinical pipeline as undervalued compared to sector peers, while discussing the possibility of a major partnership or acquisition as they look toward key meetings and data presentations later this spring.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending as investors weigh its long-term potential in the decentralized finance sector, with many discussing its fundamental value, tokenomics, and recent protocol upgrades. While some community members remain focused on long-term accumulation and the potential for a larger breakout, others are debating the impact of ongoing market volatility and the competitive landscape of lending protocols.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently in the spotlight as investors brace for the upcoming BlueBird 7 launch, with the community actively debating whether the stock is primed for a major breakout or if the event remains priced in. Investors are closely monitoring manufacturing progress and batch shipment updates as key catalysts, while discussions remain polarized between those confident in long-term deployment goals and others wary of execution timelines and institutional selling pressure.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as investors digest news regarding its potential role in U.S. payment infrastructure alongside ongoing discussions surrounding regulatory clarity. Community sentiment remains deeply polarized, with bulls positioning for a long-term liquidity-driven breakout while bears voice skepticism over recent price action and institutional adoption timelines.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

Alaska Air Group is capturing significant attention as investors react to a mix of quarterly financial results falling short of expectations and management's cautious forward guidance amid ongoing economic uncertainty. The community is actively debating the airline's long-term growth prospects, with many pointing to strategic fleet expansion, loyalty program strength, and integration synergies as key catalysts for a potential rebound.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq is trending as the exchange pushes for SEC approval to expand to 23-hour trading, aiming to modernize market access while investors digest mixed economic data and ongoing geopolitical uncertainties. Community discussion remains heavily focused on potential market volatility, with active debates concerning the long-term impact of AI infrastructure spending and the overall resilience of the current tech-driven rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Achieve on Monday appointed physician Andrew D. Goldberg as CEO and a member of its Board of Directors.</li><li>Separately, the company also said that it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for gross proceeds up to approximately $354 million.&nbsp;</li><li>Achieve is now looking forward to launching cytisinicline for nicotine dependence in the first half of 2027.</li></ul><p><br>Shares of Achieve Life Sciences Inc. (ACHV) gained 42% on Thursday after the company appointed a new CEO, shortly after announcing a private placement of up to $354 million, as it gears towards getting regulatory approval for its experimental drug for the treatment of nicotine dependence.</p><p>The stock is on track to clock its best day since February 2019, if gains hold.</p><h2 class="st-heading-2">New CEO, Board Appointments</h2><p>Achieve on Monday appointed physician Andrew D. Goldberg as CEO and a member of its Board of Directors. Goldberg, who most recently served as a Portfolio Manager at Marshall Wace, will replace Richard Stewart as CEO.</p><p>The company also appointed Lucian Iancovici and Aaron E. Royston as members of the company’s board of directors.</p><h2 class="st-heading-2">Fresh Funding</h2><p>Separately, the company also said that it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities.</p><p>The placement includes an initial upfront funding of approximately $180 million and an additional amount of up to approximately $174 million on exercise of milestone-driven warrants. The net proceeds from the placement is expected to fund a clinical trial for cytisinicline for e-cigarette cessation, the commercialization of cytisinicline, and for working capital and general corporate purposes, the company said.</p><h2 class="st-heading-2">Near-Term Milestones</h2><p>Achieve is now looking forward to the U.S. Food and Drug Administration’s approval of cytisinicline as a treatment for nicotine dependence.</p><p>Earlier this week, the company said that it expects the FDA to reject its current application by June 20, provided that the agency found manufacturing concerns at its third-party manufacturing facility. Once the formal rejection is received, the company expects to resubmit its application naming &nbsp;Adare Pharma Solutions as its manufacturer for commercial supply in the fourth quarter of 2026, it said. The company continues to expect to launch cytisinicline in the first half of 2027.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around ACHV stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.</p><p>A Stocktwits user expressed optimism for the company getting acquired after approval for cytisinicline.</p><p><stembedurl>https://www.stocktwits.com/Biotech_Pharma_Investor/message/650482761</stembedurl></p><p>Another user expressed optimism for a good year following the “professional” announcements.</p><p><stembedurl>https://www.stocktwits.com/Sieppo/message/650471510</stembedurl></p><p><a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> has more than doubled over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/hubc-stock-tanks-after-massive-rally-reverse-split/cZJvo99RIDA">HUBC Stock Declines 35% After A Whopping Two-Day Rally – What’s Driving The Change In Momentum?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Achieve Life Sciences logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?

Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter. 

Equity

Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter. 


Achieve Life Sciences' (ACHV) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the firm...

What is Zacks Research's Estimate for ACHV FY2026 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Zacks Research dropped their FY2026 earnings per share estimates for shares of Achieve Life Sciences in a note issued to investors on...

HC Wainwright Has Positive Estimate for ACHV FY2026 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 earnings estimates for shares of Achieve Life Sciences in a research report issued...

Achieve Life Sciences Flags FDA Observations While Pushing Launch To 2027 For Smoking Cessation Med

Achieve Life Sciences taps Adare for cytisinicline manufacturing as stock falls; reports wider losses and shifts US launch timeline to 2027.read more...

Q1 Earnings Estimate for ACHV Issued By HC Wainwright

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Achieve Life Sciences in a research report...

HC Wainwright Reiterates "Buy" Rating for Achieve Life Sciences (NASDAQ:ACHV)

HC Wainwright reaffirmed a "buy" rating and set a $12.00 price objective on shares of Achieve Life Sciences in a research report on Wednesday...

Achieve Life Sciences Sees Unusually Large Options Volume (NASDAQ:ACHV)

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock investors acquired 2,079 call options on the company. This represents an increase of approximately 175% compared to the typical daily volume of 756 call options...

Achieve Life Sciences Q4 Earnings Call Highlights

Achieve Life Sciences (NASDAQ:ACHV) used its fourth-quarter and full-year 2025 earnings call to outline progress toward a potential U.S. launch of cytisinicline, the company's investigational therapy...

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.30	--	--	N/A
Q4 '25	-$0.29	-$0.28	2.78%	BEAT
Q3 '25	-$0.24	-$0.28	-14.75%	MISSED
Q2 '25	-$0.37	-$0.37	-1.09%	MISSED
Q1 '25	-$0.38	-$0.37	3.06%	BEAT

ACHV
Achieve Life Sciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ACHV News

ACHVAchieve Life Sciences Inc.